From: Shortage of Nab-paclitaxel in Japan and around the World: Issues in Global Information Sharing
| Date | Event | Country | Language |
|---|---|---|---|
| Aug. 13, 2021 | A website called drugshortagescanada.ca added nab-paclitaxel to the list of anticipated drug shortages, which would start from Nov. 30 because of manufacturing problems (https://www.drugshortagescanada.ca/shortage/144114, Accessed 2021-12-23). | Canada | English, French |
| Aug. 18 | Taiho Pharmaceutical Co. Ltd. released the first report for medical professionals that anticipated shortage of nab-paclitaxel would start from October because of manufacturing problems. | Japan | Japanese |
| Before Aug. 19 | The Australian Government Department of Health added nab-paclitaxel into its drug shortage list, and the government approved an unregistered product instead (https://apps.tga.gov.au/Prod/msi/Search/Tradename//133500, Accessed 2021-12-23). | Australia | English |
| Aug. 20 | Japan Federation of Cancer Patient Groups filed the petition to the Ministry of Health, Labour and Welfare, Pharmaceuticals and Medical Devices Agency, and Taiho Pharmaceutical Co. Ltd., requesting detailed information disclosure and the proper distribution of the drug (http://zenganren.jp/?p=3517, Accessed 2021-12-23). | Japan | Japanese |
| Aug. 26 | Related academic societies released a joint statement for medical professionals in Japan, requesting using other options for cancer treatment in possible cases (https://www.jbcs.gr.jp/uploads/files/info/Joint Statement.pdf, Accessed 2021-12-23). | Japan | Japanese |
| Taiho Pharmaceutical Co. Ltd. released the first report for the patients and their families. | Japan | Japanese | |
| Sep. 16 | Taiho Pharmaceutical Co. Ltd. released the press release that the supply of nab-paclitaxel would meet the demand in Japan until mid-November as a result of stock adjustment and shipment adjustment. | Japan | Japanese |
| Oct. 4 | The Food and Drug Administration added nab-paclitaxel to the drug shortage list. | United States | English |
| Nov. 11 | Taiho Pharmaceutical Co. Ltd. released the press release that the supply of nab-paclitaxel would meet the demand in Japan until late-January under the condition that hospitals spared the use of the drug to the patients who had alternatives. | Japan | Japanese |
| Dec. | First communication from Bristol Myers Squibb appeared on the Food and Drug Administration website. | United States | English |
| Dec. 16 | Taiho Pharmaceutical Co. Ltd. released the press release that the supply of nab-paclitaxel would meet the demand in Japan until late-February. | Japan | Japanese |
| Jan. 24, 2022 | Taiho Pharmaceutical Co. Ltd. released the press release that the supply of nab-paclitaxel would meet the demand in Japan until July. | Japan | Japanese |
| Apr. | Bristol Myers Squibb stated that the manufacture of nab-paclitaxel returned to normal on the Food and Drug Administration website. | United States | English |
| Apr. 19 | Taiho Pharmaceutical Co. Ltd. released the press release that the manufacture of nab-paclitaxel returned to normal and that the supplies would return to the normal in June. | Japan | Japanese |
